Overcoming Resistance Mechanisms and Addressing Unmet Needs

Panelists discuss how resistance to EGFR tyrosine kinase inhibitors remains a key barrier to long-term disease control in non–small cell lung cancer.

They review common resistance mechanisms, such as secondary mutations (T790M, C797S), pathway activation, and histologic transformation, emphasizing how tumor heterogeneity complicates durable response.

The conversation highlights the importance of developing next-generation inhibitors, combination regimens, and central nervous system–penetrant agents. Panelists also address unmet needs, including improved testing, sequencing strategies, and access to emerging agents to ensure sustained clinical benefit and better outcomes across patient populations.